Business Wire

IKOULA CLOUD BACKUP, by Acronis : New Flexible and Secure Backup Solution

8.7.2019 11:00:00 EEST | Business Wire | Press release

Share

In the digital age and in the face of the resurgence of cyberattacks, the safeguarding of data becomes an absolute necessity. The scale of attacks spares no business and government, as evidenced the ransomware attack experienced by the city of Baltimore (USA). To help organizations better protecting themselves against the loss or theft of data, IKOULA - Cloud hosting specialist - has developed IKOULA CLOUD BACKUP, by Acronis, a new simple, customizable, flexible and secure, cloud backup solution, in "BaaS" (Backup as a Service) mode.

IKOULA CLOUD BACKUP, by Acronis is an easy-to-use, reliable, automated and scalable cloud backup solution. Easy to deploy, without hardware investment, it can protect all data, applications or files, workstations, mobile devices, and physical or virtual servers.

On the security side, all transferred data are encrypted using an AES-256 encryption algorithm and their access is protected by a unique encryption key without which data recovery is impossible. The solution also includes ransomware protection software. Cloud backup offers a higher level of redundancy and security; Users are thus assured of the total availability of strategic data in the event of a disaster on site or remotely.

Among other assets, usuers have the ability to remotely administer, via a web console, all the physical and virtual terminals of their environment. They can define backups to do, from simple document to full server, automate frequencies and restore all or part from the cloud, at any time and from anywhere.

For more information, visit: https://www.ikoula.com/en/acronis?utm_source=businesswire.com&utm_medium=text&utm_campaign=acronis

To learn how creating your backup easily, please check our video here : https://www.youtube.com/watch?v=4GVMADHw008&vl=zh-Hans

ABOUT IKOULA:

Pioneer of the French Cloud since 1998, IKOULA owns its own Datacenters in France (Reims and Laon), as well as two subsidiaries in Spain and the Netherlands. Because Human Being is part of its DNA, IKOULA maintains a close relationship with its customers, and puts at their disposal reactive teams of experts, available 24/7, able to advise them and accompany them in their activities. IKOULA's teams are multilingual, in order to meet the internationalization challenges of all its customers, spread over more than 60 countries on 4 continents.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

IKOULA :
Laurane VASSOR ARCARO – +33 01 84 01 02 69
lvassorarcaro@ikoula.com

Agency :
Céline BERNARD - +33 06.10.78.41.73
Celinebernard_rp@outlook.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Newmont Announces Key Executive Appointments for the Next Phase of Delivery16.6.2026 00:20:00 EEST | Press release

Newmont Corporation (NYSE: NEM, ASX: NEM, PNGX: NEM) (“Newmont”) today announced leadership appointments that further shape its go-forward Executive Leadership Team under President and Chief Executive Officer Natascha Viljoen and reflect the depth of leadership talent within the company. Effective July 1, 2026, Brian Tabolt has been appointed Chief Financial Officer, Mark Rodgers has been appointed Chief Operating Officer, and David Thornton has been appointed Chief Technical Officer. In addition, David Fry has been promoted to Executive Vice President, Project Development, reflecting the importance of disciplined project development and execution as Newmont advances its highest-return growth opportunities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615487768/en/ Mark Rodgers - COO “These appointments bring together respected leaders with deep industry experience and a strong understanding of our operational, financia

Westlake Expands Global Chlorovinyls Manufacturing Capacity With Acquisition of PVC and VCM Plants in Wilhelmshaven, Germany15.6.2026 21:18:00 EEST | Press release

Westlake Corporation (NYSE: WLK) (“Westlake”) announced today that its German subsidiary, Westlake Vinnolit GmbH & Co. KG, has completed the previously-announced acquisition of a polyvinyl chloride and vinyl chloride monomer production site located in Wilhelmshaven, Germany (the “Wilhelmshaven plant”). The Wilhelmshaven plant, which was previously in insolvency administration, has the capacity to produce 380,000 metric tons of PVC per year. “This acquisition strengthens our Performance & Essential Materials business by expanding our global chlorovinyls manufacturing footprint and complements our existing chlorovinyl production facilities in Europe and North America,” said Jean-Marc Gilson, President and Chief Executive Officer of Westlake. “The Wilhelmshaven plant, which is located in Lower Saxony on Germany’s North Sea coast, benefits from advantageous logistical infrastructure, including a deep-water dock that enables efficient raw-materials supply. We look forward to welcoming the s

Onera Announces Integration of the Onera hPSG® Solution With Somnoware15.6.2026 20:35:00 EEST | Press release

Onera Health, a leader in transforming sleep medicine, announces that its end-to-end home polysomnography solution, the Onera hPSG® solution, now integrates with Somnoware by ResMed sleep lab management software. This integration enables clinicians to conduct Polysomnography tests (PSGs) where patients sleep most comfortably, in their own home, while managing the entire workflow in Somnoware. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615106079/en/ Onera hPSG®, an end-to-end home polysomnography solution from Onera Health, is now integrated into Somnoware, enabling their shared customers to conduct Polysomnography tests (PSGs) in the patient's home while managing the entire workflow in Somnoware. “The integration with Somnoware is a welcomed enhancement that broadens access to the Onera hPSG® solution,” states Ruben de Francisco, Founder and CEO of Onera Health. “Many sleep centers are customers of both Onera and Somn

Digital Cooperation Organization Launches Global Expert Community to Accelerate International Digital Cooperation15.6.2026 19:18:00 EEST | Press release

The Digital Cooperation Organization (DCO), the world's first standalone international organization dedicated to inclusive and sustainable digital economy growth, today announced the launch of the Global Expert Community (GEC) — a new platform designed to mobilize expertise and advance international collaboration in support of high-impact digital initiatives across DCO Member States and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615565781/en/ Digital Cooperation Organization Launches Global Expert Community to Accelerate International Digital Cooperation (Graphic: AETOSWire) The GEC reflects the DCO's continued commitment to turning digital cooperation into action by expanding access to specialized expertise and strengthening collaboration across sectors and borders. As digital transformation reshapes economies and societies worldwide, the Community is designed to convert global perspectives and practical expe

New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 115.6.2026 19:00:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK)today presented additional results from two pivotal studies at SLEEP 2026, showing oveporexton (TAK-861), an oral orexin receptor 2 (OX2R)-selective agonist, improved daily functioning as well as cognitive and sleep-related symptoms associated with narcolepsy type 1 (NT1).1,2,3 Oveporexton is designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. These data, along with previously disclosed Phase 3 results, demonstrated improvement across the broad disease spectrum, supporting the potential of oveporexton to redefine the standard of care for NT1.4 "Narcolepsy type 1 is a 24-hour disease driven by orexin deficiency, and while excessive daytime sleepiness and cataplexy are the most recognized symptoms, many people experience additional bothersome symptoms such as cognitive difficulties and disrupted nighttime sleep," said Emmanuel Mignot, M.D., Ph.D., principal investigator for the FirstLight (TAK-861-3001) Phase 3 stu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye